Phillip W. Janowicz

Phillip W. Janowicz

Auto-generated profile, based on publicly available information

Phillip W. Janowicz

Image X Institute, Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2017 in Brain
Verified
Journal Article
Open access
PDF file
RNRebecca Maree Nisbet
Rebecca Maree Nisbet
AJAnn Van der Jeugd
Ann Van der Jeugd
GLGerhard Leinenga
Gerhard Leinenga
HEHarrison T. Evans
Harrison T. Evans
PJPhillip W. Janowicz
Phillip W. Janowicz
JGJürgen Götz
Jürgen Götz
Alzheimer’s disease is characterized by the deposition of amyloid-β as extracellular plaques and hyperphosphorylated tau as intracellular neurofibrillary tangles. Tau pathology characterizes not only Alzheimer’s disease, but also many other tauopathies, presenting tau as an attractive therapeutic target. Passive tau immunotherapy has been previously explored; however, because only a small fraction of peripherally delivered antibodies crosses the blood–brain barrier, enters the brain and engages with tau that forms intracellular aggregates, more efficient ways of antibody delivery and neuronal uptake are warranted. In the brain, tau exists as multiple isoforms. Here, we investigated the efficacy of a novel 2N tau isoform-specific single chain antibody fragment, RN2N, delivered by passive immunization in the P301L human tau transgenic pR5 mouse model. We demonstrate that, in treated mice, RN2N reduces anxiety-like behaviour and phosphorylation of tau at distinct sites. When administration of RN2N was combined with focused ultrasound in a scanning mode (scanning ultrasound), RN2N delivery into the brain and uptake by neurons were markedly increased, and efficacy was significantly enhanced. Our study provides evidence that scanning ultrasound is a viable tool to enhance the delivery of biologics across the blood–brain barrier and improve therapeutic outcomes and further presents single-chain antibodies as an alternative to full-length antibodies.

1 May 2020 in Biomaterials
Verified
Journal Article
Closed access
MLMarietta Landgraf
Marietta Landgraf
CLChristoph A. Lahr
Christoph A. Lahr
IKIshdeep Kaur
Ishdeep Kaur
ASAbbas Shafiee
Abbas Shafiee
ASAlvaro Sanchez-Herrero
Alvaro Sanchez-Herrero
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher

25 June 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PJPhillip W. Janowicz
Phillip W. Janowicz
GLGerhard Leinenga
Gerhard Leinenga
JGJürgen Götz
Jürgen Götz
RNRebecca Maree Nisbet
Rebecca Maree Nisbet
The microtubule-associated protein tau is an attractive therapeutic target for the treatment of Alzheimer’s disease and related tauopathies as its aggregation strongly correlates with disease progression and is considered a key mediator of neuronal toxicity. Delivery of most therapeutics to the brain is, however, inefficient, due to their limited ability to cross the blood-brain barrier (BBB). Therapeutic ultrasound is an emerging non-invasive technology which transiently opens the BBB in a focused manner to allow peripherally delivered molecules to effectively enter the brain. In order to open a large area of the BBB, we developed a scanning ultrasound (SUS) approach by which ultrasound is applied in a sequential pattern across the whole brain. We have previously shown that delivery of an anti-tau antibody in a single-chain variable fragment (scFv) format to the brain is increased with SUS allowing for an enhanced therapeutic effect. Here we compared the delivery of an anti-tau antibody, RN2N, in an scFv, fragment antigen-binding (Fab) and full-sized immunoglobulin G (IgG) format, with and without sonication, into the brain of pR5 tau transgenic mice, a model of tauopathy. Our results revealed that the full-sized IgG reaches a higher concentration in the brain compared with the smaller formats by bypassing renal excretion. No differences in either the ultrasound-mediated uptake or distribution in the brain from the sonication site was observed across the different antibody formats, suggesting that ultrasound can be used to successfully increase the delivery of therapeutic molecules of various sizes into the brain for the treatment of neurological diseases.

17 February 2022 in Biomaterials
Verified
Journal Article
Closed access
PJPhillip W. Janowicz
Phillip W. Janowicz
ZHZachary H. Houston
Zachary H. Houston
JBJens Bunt
Jens Bunt
NFNicholas Fletcher
Nicholas Fletcher
CBCraig A. Bell
Craig A. Bell
Kris ThurechtKris Thurecht
Kris Thurecht

24 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PJPhillip W. Janowicz
Phillip W. Janowicz
TBThomas Boele
Thomas Boele
RMRichard T. Maschmeyer
Richard T. Maschmeyer
YGYaser H. Gholami
Yaser H. Gholami
EKEmma G. Kempe
Emma G. Kempe
DWDavid Waddington
David Waddington
Detecting glioblastoma infiltration in the brain is challenging due to limited MRI contrast beyond the enhancing tumour core. This study aims to investigate the potential of superparamagnetic iron oxide nanoparticles (SPIONs) as contrast agents for improved detection of diffuse brain cancer. We examine the distribution and pharmacokinetics of SPIONs in glioblastoma models with intact and disrupted blood-brain barriers. Using MRI, we imaged RN1-luc and U87MG mice injected with Gadovist and SPIONs, observing differences in blood-brain barrier permeability. Peripheral imaging showed strong uptake of nanoparticles in the liver and spleen, while vascular and renal signals were transient. Susceptibility gradient mapping enabled positive nanoparticle contrast within tumours and provided additional information on tumour angiogenesis. This approach offers a novel method for detecting diffuse brain cancer. Our findings demonstrate that SPIONs enhance glioblastoma detection beyond conventional MRI, providing insights into tumour angiogenesis and opening new avenues for early diagnosis and targeted treatment strategies.

6 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
PJPhillip W. Janowicz
Phillip W. Janowicz
TBThomas Boele
Thomas Boele
RMRichard T. Maschmeyer
Richard T. Maschmeyer
YGYaser H. Gholami
Yaser H. Gholami
EKEmma G. Kempe
Emma G. Kempe
DWDavid Waddington
David Waddington
Detecting glioblastoma infiltration in the brain is challenging due to limited MRI contrast beyond the enhancing tumour core. This study aims to investigate the potential of superparamagnetic iron oxide nanoparticles (SPIONs) as contrast agents for improved detection of diffuse brain cancer. We examine the distribution and pharmacokinetics of SPIONs in glioblastoma models with intact and disrupted blood-brain barriers. Using MRI, we imaged RN1-luc and U87MG mice injected with Gadovist and SPIONs, observing differences in blood-brain barrier permeability. Peripheral imaging showed strong uptake of nanoparticles in the liver and spleen, while vascular and renal signals were transient. Susceptibility gradient mapping enabled positive nanoparticle contrast within tumours and provided additional information on tumour angiogenesis. This approach offers a novel method for detecting diffuse brain cancer. Our findings demonstrate that SPIONs enhance glioblastoma detection beyond conventional MRI, providing insights into tumour angiogenesis and opening new avenues for early diagnosis and targeted treatment strategies.